FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197481289> ?p ?o ?g. }

• W3197481289 endingPage "1379" @default.
• W3197481289 startingPage "1379" @default.
• W3197481289 abstract "Imbalance between oxidative stress burden and antioxidant capacity is implicated in the course of atherosclerosis among type 2 diabetic patients. We addressed the effects of insulin, glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and their combination on levels of oxidant and antioxidant biomarkers. We recruited a total of 160 type 2 diabetics, who received insulin (n = 40), liraglutide (n = 40), empagliflozin (n = 40), or their combination (GLP-1RA+SGLT-2i) (n = 40). We measured at baseline, at 4 and at 12 months of treatment: (a) Thiobarbituric Acid Reactive Substances (TBARS), (b) Malondialdehyde (MDA), (c) Reducing Power (RP), (d) 2,2¢-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical (ABTS) and (e) Total Antioxidant Capacity TAC). Dual treatment resulted in significant improvement of TBARS, MDA, and ABTS at four months compared with the other groups (p < 0.05 for all comparisons). At twelve months, all participants improved TBARS, MDA, and ABTS (p < 0.05). At 12 months, GLP1-RA and GLP-1RA+SGLT2-i provided a greater reduction of TBARS (−8.76% and −9.83%) compared with insulin or SGLT2i (−0.5% and 3.22%), (p < 0.05). GLP1-RA and GLP-1RA+SGLT-2i showed a greater reduction of MDA (−30.15% and −31.44%) compared with insulin or SGLT2i (4.72% and −3.74%), (p < 0.05). SGLT2i and GLP-1RA+SGLT2-i showed increase of ABTS (12.87% and 14.13%) compared with insulin or GLP1-RA (2.44% and −3.44%), (p < 0.05). Only combined treatment resulted in increase of TAC compared with the other groups after 12 months of treatment (p < 0.05).12-month treatment with GLP1-RA and SGLT2i resulted in reduction of biomarkers responsible for oxidative modifications and increase of antioxidant biomarker, respectively. The combination treatment was superior and additive to each separate agent and also the beneficial effects appeared earlier." @default.
• W3197481289 created "2021-09-13" @default.
• W3197481289 creator A5004112938 @default.
• W3197481289 creator A5004825622 @default.
• W3197481289 creator A5006804248 @default.
• W3197481289 creator A5009013499 @default.
• W3197481289 creator A5024241997 @default.
• W3197481289 creator A5024861008 @default.
• W3197481289 creator A5032188059 @default.
• W3197481289 creator A5042599698 @default.
• W3197481289 creator A5043350018 @default.
• W3197481289 creator A5045869380 @default.
• W3197481289 creator A5056286192 @default.
• W3197481289 creator A5058783272 @default.
• W3197481289 creator A5062707519 @default.
• W3197481289 creator A5076796959 @default.
• W3197481289 creator A5079322916 @default.
• W3197481289 creator A5086451568 @default.
• W3197481289 date "2021-08-28" @default.
• W3197481289 modified "2023-10-10" @default.
• W3197481289 title "Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes" @default.
• W3197481289 cites W1689732359 @default.
• W3197481289 cites W1821804635 @default.
• W3197481289 cites W1979035500 @default.
• W3197481289 cites W1988049600 @default.
• W3197481289 cites W1992011763 @default.
• W3197481289 cites W1996902548 @default.
• W3197481289 cites W2004853818 @default.
• W3197481289 cites W2008026539 @default.
• W3197481289 cites W2010116948 @default.
• W3197481289 cites W2014694123 @default.
• W3197481289 cites W2016818962 @default.
• W3197481289 cites W2023244494 @default.
• W3197481289 cites W2024965702 @default.
• W3197481289 cites W2035907631 @default.
• W3197481289 cites W2041661268 @default.
• W3197481289 cites W2055213286 @default.
• W3197481289 cites W2060157112 @default.
• W3197481289 cites W2060213751 @default.
• W3197481289 cites W2060940255 @default.
• W3197481289 cites W2066000449 @default.
• W3197481289 cites W2068417527 @default.
• W3197481289 cites W2083485319 @default.
• W3197481289 cites W2088107199 @default.
• W3197481289 cites W2105731956 @default.
• W3197481289 cites W2109069544 @default.
• W3197481289 cites W2109286159 @default.
• W3197481289 cites W2126528640 @default.
• W3197481289 cites W2137188853 @default.
• W3197481289 cites W2150959326 @default.
• W3197481289 cites W2153908199 @default.
• W3197481289 cites W2163741655 @default.
• W3197481289 cites W2267150166 @default.
• W3197481289 cites W2399139263 @default.
• W3197481289 cites W2402599050 @default.
• W3197481289 cites W2460530547 @default.
• W3197481289 cites W2557156634 @default.
• W3197481289 cites W2587769401 @default.
• W3197481289 cites W2607109151 @default.
• W3197481289 cites W2607248396 @default.
• W3197481289 cites W2613259257 @default.
• W3197481289 cites W2619744261 @default.
• W3197481289 cites W2740695644 @default.
• W3197481289 cites W2745418757 @default.
• W3197481289 cites W2755249976 @default.
• W3197481289 cites W2780874826 @default.
• W3197481289 cites W2782989965 @default.
• W3197481289 cites W2784607695 @default.
• W3197481289 cites W2793795908 @default.
• W3197481289 cites W2795816442 @default.
• W3197481289 cites W2801396070 @default.
• W3197481289 cites W2852375780 @default.
• W3197481289 cites W2894993577 @default.
• W3197481289 cites W2900940745 @default.
• W3197481289 cites W2911996337 @default.
• W3197481289 cites W2914361491 @default.
• W3197481289 cites W2969411997 @default.
• W3197481289 cites W2970272830 @default.
• W3197481289 cites W2981565698 @default.
• W3197481289 cites W2988212132 @default.
• W3197481289 cites W2989806579 @default.
• W3197481289 cites W2996083274 @default.
• W3197481289 cites W3003546904 @default.
• W3197481289 cites W3020052200 @default.
• W3197481289 cites W3023502411 @default.
• W3197481289 cites W3031341062 @default.
• W3197481289 cites W3033380947 @default.
• W3197481289 cites W3048562226 @default.
• W3197481289 cites W3130197230 @default.
• W3197481289 cites W565056258 @default.
• W3197481289 doi "https://doi.org/10.3390/antiox10091379" @default.
• W3197481289 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8468804" @default.
• W3197481289 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34573011" @default.
• W3197481289 hasPublicationYear "2021" @default.
• W3197481289 type Work @default.
• W3197481289 sameAs 3197481289 @default.
• W3197481289 citedByCount "14" @default.
• W3197481289 countsByYear W31974812892022 @default.

• next